Idalopirdine-based combinatorial therapies of alzheimer's disease

Abstract

The present invention relates to combinatorial therapies and methods for the treatment of Alzheimer's disease or an Alzheimer's disease related disorder based on idalopirdine, baclofen and acamprosate, wherein idalopirdine is provided as suboptimal doses.

Description

technical field

[0001] The present invention relates to novel combinations and methods for the treatment of Alzheimer's disease and related diseases. More specifically, the present invention relates to novel combination treatments for Alzheimer's disease and related diseases based on idalopirdine, baclofen and acamprosate. Background technique

[0002] Alzheimer's disease (AD) is a prototypical cortical dementia characterized by memory impairment accompanied by speech difficulties (language impairment in which speech and language comprehension are impaired), movement disorders (in the absence of motor or sensory impairment Inability to coordinate and execute certain voluntary movements and gestures) and cognitive impairment (inability to recognize objects, people, sounds, shapes, or smells), which can be attributed to the involvement of relevant areas of the cortex. Specific symptoms such as spastic paraplegia (weakness affecting the lower extremities) may also be involved ...

Examples

Embodiment

[0170] A - Combination therapy of the invention prevents Aβ in vivo 25-42 Cognitive impairment due to toxicity

[0171] Peptide amyloid-beta 25-35 (Aβ 25-35 ) is the hydrophobic portion of the full-length amyloid peptide. Injection of this peptide into the ventricles of rodents is known to induce a progressive neurodegenerative process leading to cognitive deficits. This model is commonly used in disorders involving symptoms of cognitive impairment [49-53]. The results of this example demonstrate that the combination of idalopirdine (at a suboptimal dose), baclofen and acamprosate is not only effective but also acts synergistically to protect treated animals from neurodegeneration due to injection of toxic peptides process.

[0172] treatment solutions

[0173] Male Swiss mice were administered from day 0 to day 10:

[0174] - fake products (groups 1 and 2);

[0175] - Baclofen, acamprosate and idalopirdine at 0.480 mg / kg, 0.032 mg / kg and 4.5 mg / kg respectively (group ...

technical field

[0001] The present invention relates to novel combinations and methods for the treatment of Alzheimer's disease and related diseases. More specifically, the present invention relates to novel combination treatments for Alzheimer's disease and related diseases based on idalopirdine, baclofen and acamprosate. Background technique

[0002] Alzheimer's disease (AD) is a prototypical cortical dementia characterized by memory impairment accompanied by speech difficulties (language impairment in which speech and language comprehension are impaired), movement disorders (in the absence of motor or sensory impairment Inability to coordinate and execute certain voluntary movements and gestures) and cognitive impairment (inability to recognize objects, people, sounds, shapes, or smells), which can be attributed to the involvement of relevant areas of the cortex. Specific symptoms such as spastic paraplegia (weakness affecting the lower extremities) may also be involved ...

Examples

Embodiment

[0170] A - Combination therapy of the invention prevents Aβ in vivo 25-42 Cognitive impairment due to toxicity

[0171] Peptide amyloid-beta 25-35 (Aβ 25-35 ) is the hydrophobic portion of the full-length amyloid peptide. Injection of this peptide into the ventricles of rodents is known to induce a progressive neurodegenerative process leading to cognitive deficits. This model is commonly used in disorders involving symptoms of cognitive impairment [49-53]. The results of this example demonstrate that the combination of idalopirdine (at a suboptimal dose), baclofen and acamprosate is not only effective but also acts synergistically to protect treated animals from neurodegeneration due to injection of toxic peptides process.

[0172] treatment solutions

[0173] Male Swiss mice were administered from day 0 to day 10:

[0174] - fake products (groups 1 and 2);

[0175] - Baclofen, acamprosate and idalopirdine at 0.480 mg / kg, 0.032 mg / kg and 4.5 mg / kg respectively (group ...

Images